Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Mounjaro can cause reflux and indigestion in some people. Clinical trial data from the SURMOUNT programme recorded gastro-oesophageal reflux and indigestion among the reported gastrointestinal side effects of tirzepatide, the active ingredient. These symptoms are linked to the way the medicine slows gastric emptying, meaning food and stomach acid sit in the stomach longer than usual. Most people who experience reflux on Mounjaro find it is mild to moderate and tends to ease as the body adjusts, particularly after the first few weeks at a new dose. It is worth knowing before you start that this is a recognised pattern, not a sign that treatment has gone wrong. Mounjaro is a prescription-only medicine, and a GPhC-registered Independent Prescriber will assess your full medical history, including any pre-existing reflux conditions, before treatment is considered appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, which followed 2,539 adults with obesity over 72 weeks, captured adverse event data across all tirzepatide doses. Gastrointestinal events as a category were the most commonly reported side effects, and within that group, gastro-oesophageal reflux disease, dyspepsia and eructation (burping) featured alongside the headline symptoms of nausea and diarrhoea. The NHS medicines page for tirzepatide lists indigestion and acid reflux among the side effects that affect more than one in a hundred people. Crucially, rates were higher at dose increases and generally fell back as participants remained at a stable dose. That trajectory matters: it suggests the stomach is adapting rather than being permanently altered. Severity was described as mild to moderate in the majority of cases, and discontinuation due to reflux alone was uncommon. None of this means everyone experiences it, but reflux is common enough that it is worth anticipating rather than being caught off guard.
The mechanism fits the biology. Tirzepatide activates both GIP and GLP-1 receptors, which together slow gastric emptying considerably. When digestion slows, the lower oesophageal sphincter faces prolonged pressure from stomach contents, making reflux more likely. If you want to understand more about how Mounjaro and reflux are connected, including why this side effect is so closely tied to the drug's mechanism, we have covered the topic in full. This is the same pathway behind the nausea pattern on GLP-1 medicines generally, and it explains why reflux and burping often arrive together.
A question our prescribers hear most weeks is whether reflux means the dose needs to come down. The honest answer is: not automatically. Reflux on Mounjaro tends to cluster around two moments — the first few weeks of treatment, when the stomach is adjusting to delayed emptying, and the first one to two weeks after each dose step up. Outside those windows, many people find their digestive symptoms quieten considerably.
Food choices matter more than most people realise at the outset. Large meals are the single biggest driver because they increase stomach volume and pressure. High-fat foods compound this by further slowing emptying on top of what tirzepatide is already doing. Caffeine and alcohol both relax the lower oesophageal sphincter, and carbonated drinks add gas pressure. None of these are outright banned, but the combination of a fatty late-night meal, a glass of wine, and a large portion is reliably associated with a difficult night for people on GLP-1 treatment. Eating more slowly also helps, the natural appetite suppression Mounjaro produces means it is easy to overeat before fullness signals reach the brain, particularly early in treatment.
Position after eating has a straightforward effect too. Lying down within two to three hours of a meal gives stomach contents an easier route back towards the oesophagus. A short walk, or simply staying seated and upright, reduces that risk without any additional intervention. For a practical guide to managing acid reflux specifically on Mounjaro, we have covered the main approaches in detail, including when symptoms warrant a prescriber conversation.
For people who already live with gastro-oesophageal reflux disease before starting treatment, the picture needs a bit more care. Tirzepatide's effect on gastric emptying is not trivially additive on top of existing reflux, it can amplify symptoms during dose escalation in ways that benefit from proactive management rather than waiting to see. This is not a reason to avoid treatment; the clinical guidance for prescribers notes that pre-existing GI conditions are factors to weigh in the benefit-risk assessment, not automatic exclusions.
If you are already taking a proton pump inhibitor or H2 blocker, your prescriber will want to know. Timing of those medicines relative to meals and Mounjaro can make a meaningful difference. Our page on Mounjaro and acid reflux goes into further detail on how existing conditions can interact with tirzepatide and what adjustments can help. The full side-effect profile of Mounjaro covers the GI picture comprehensively, including which symptoms warrant prompt medical attention. For context on how tirzepatide's GI effects compare with semaglutide, the tirzepatide reflux overview draws out the relevant distinctions.
One category of symptom should not be attributed to reflux and managed with dietary tweaks alone: severe, persistent stomach pain that radiates through to the back, with or without vomiting, needs urgent medical assessment. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis as an infrequent but serious risk, the presentation can mimic severe reflux or indigestion, which is precisely why it needs to be taken seriously and reported. Any suspected side effect can also be reported directly via the Yellow Card scheme.
Reflux that is mild and linked clearly to meals is reasonable to manage with the practical steps above for the first couple of weeks at a new dose. Reflux that is persistent, disruptive to sleep, or worsening rather than settling is a reason to speak to your prescriber. Dose timing, dose escalation pace, and concurrent medication can all be adjusted. Some patients do better progressing through the dose schedule more gradually; that is a clinical decision, not a one-size prescription. Understanding the full scope of how Mounjaro works can help you have a more productive conversation about your specific symptoms.
If you are considering treatment and want to talk through your existing GI history before committing, our consultation is the right starting point. There is no fee for that initial assessment. Speak to our prescribers and get a clear picture of whether Mounjaro is a suitable option for you, reflux history included.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.